Hughes Hubbard, S&C Advise on Merck's Idenix Buy

, The Am Law Daily

   | 0 Comments

Moving to expand its product offerings aimed at treating hepatitis C, pharmaceutical giant Merck & Co. announced Monday that it has agreed to buy Cambridge, Ma.-based Idenix Pharmaceuticals Inc. for $3.85 billion.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202658714211

Thank you!

This article's comments will be reviewed.